Table 1. Percentage of relapsing mice and bacterial burden in mice vaccinated SC or IN with MVATG18598 or empty vector, MVATGN33.1, during or after antibiotic regimen.
| Treatment | Vaccination Route | Positioning vs. RHZ | Relapses | Bacterial load at relapse CFU (log10) (mean ± SEM) |
|
|---|---|---|---|---|---|
| Proportion | % | ||||
| RHZ | - | - | 15 / 15 | 100 | 2.6 ± 0.3 |
| RHZ + MVATGN33.1 | SC | During | 10 / 15 | 67 | 2.3 ± 0.5 |
| RHZ + MVATG18598 | 9 / 15 | 60 | 1.3 ± 0.4 | ||
| RHZ + MVATGN33.1 | After | 13 / 15 | 87 | 2.4 ± 0.4 | |
| RHZ + MVATG18598 | 10 / 14a | 71 | 2.2 ± 0.4 | ||
| RHZ + MVATGN33.1 | IN | During | 10 / 15 | 67 | 2.1 ± 0.4 |
| RHZ + MVATG18598 | 10 / 15 | 67 | 2.4 ± 0.5 | ||
| RHZ + MVATGN33.1 | After | 14 / 15 | 93 | 3.3 ± 0.3 | |
| RHZ + MVATG18598 | 13 / 15 | 87 | 2.7 ± 0.4 | ||
R, Rifampin; H, Isoniazid; Z, Pyrazinamide.
SC, Subcutaneous; IN, Intranasal
aOne mouse died during the experiment.